Xenon: FOS read-across in MDD, BD hitches with Kv7?

The pause of trials with Kv7 potassium channel opener azetukalner in other indications cast a pall over the better news from Xenon Pharmaceuticals Inc. that the firm has submitted an NDA to the U.S. FDA for the same drug in focal onset seizures (FOS).